- Review Article
- Published:
Evidence-based prevention (EBP): A review of cytochrome P450 expression in the bronchial epithelium and new approach to lung cancer prevention
Environmental Health and Preventive Medicine volume 11, pages 97–101 (2006)
Abstract
The number of fatalities in Japan attributable to lung cancer exceeded 50000 in 2001. It is socially desirable that various markers, which can be utilized for the prevention of lung cancer, be established. We believe that smoking or exposure to carcinogens in air induces mutations in bronchial and alveolar epithelia, leading to the development of lung cancer. It would be useful to have markers of individual differences in susceptibility to chemical carcinogen-induced lung cancer 1) to identify genetic polymorphisms of enzymes metabolizing chemical carcinogens and 2) to investigate the expression of enzymes metabolizing chemical carcinogens. In this paper, we review CYP expression in the bronchial epithelium. CYP1, CYP2 and CYP3 are expressed in the bronchial epithelium. We also show the relationship between the genetic polymorphisms of cytochrome P450 (CYP) and a person’s susceptibility to chemical carcinogen-induced lung cancer. We demonstrate the relationship between cigarette consumption and the CYP expression profile in the bronchial epithelium. To maintain and promote public health, we must apply evidence, such as CYP polymorphisms and CYP profiles to disease prevention and also to aggressively advance evidence-based prevention (EBP) of lung cancer.
Abbreviations
- CYP:
-
cytochrome P450
- SNP:
-
single-nucleotide polymorphism
- EBP:
-
evidence-based prevention
References
Uramoto H, Nakanishi R, Fujino Y, Imoto H, Takenoyama M, Yoshimatsu T, et al. Prediction of pulmonary complications after a lobectomy in patients with non-small cell lung cancer. Thorax. 2001; 56: 59–61.
Osaki T, Mitsudomi T, Oyama T, Nakanishi R, Yasumoto K. Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest. 1995; 108: 157–162.
Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer; Impact on recurrence and survival. Ann Surg. 2001; 233: 133–139.
Osaki T, Oyama T, Inoue M, Gu CD, Kodate M, Aikawa M, et al. Molecular biological markers and micrometastasis in reseeted non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg. 2001; 49: 545–551.
Osaki T, Ovama T, Gu CD, Yamashita T, So T, Takenoyama M, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage 1 non-small-cell lung cancer. J Clin Oncol. 2002; 20: 2930–2936.
Oyma T, Kawamoto T, Matsuno M, Osaki T, Matsumoto A, Isse T, et al. A case-case study comparing the usefulness of serum trace elements (Cu, Zn and Se) and tumor markers (CEA, SCC and SLX) in non-small cell lung cancer patients. Anticancer Res. 2003; 23: 605–612.
Gu CD, Oyama T, Osaki T, Li J, Takenoyama M, Izumi H, et al. Low expression of polypeptide GalNac N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: Impact on poor prognosis and early recurence. Br J Cancer. 2004; 90: 436–442.
Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, et al. Expression of delta Np73 predicts poor prognosis in lung cancer. Clin Cancer Res. 2004; 10: 6905–6911.
Iwata T, Uramoto H, Sugio K, Fujino Y, Oyama T, Nakata S, et al. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer. Lung Cancer. 2005; 50: 67–73.
Oyama T, Osaki T, Baba T, Nagata Y, Mizukami M, So T, et al. Molecular genetic tumor markers in non-small cell lung cancer. Anticancer Res. 2005; 25: 1193–1196.
Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer. 2005; 49: 55–62.
Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, et al. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer. 2005 (in press).
Yoshimatsu T, Uramoto H, Oyama T, Yashima Y, Gu C, Morita M, et al. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer. Anticancer Res. 2005; 25: 3437–3443.
Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst. 1993; 85: 2018–2023.
Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K, et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res. 1996; 2: 1185–1189.
Kawamoto T, Isse T, Kumugita N, Yang M, Kitagawa K, Suenaga R, et al. Effects of genetic polymorphism of drug metabolizing enzymes on smoking and drinking. J UOEH. 2003; 25: 97–106.
Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992; 268: 2420–2425.
Oyama T, Kawamoto T, Matsumoto A, Isse T, Ozaki S, Yasumoto K. Evidence based prevention (EBP): Evidencebased approach to prevention of lung cancer by application of cytochrome 2E1 polymorphism. J UOEH. 2002; 24: 413–421.
Oyama T, Matsumoto A, Isse T, Kim Y-D, Ozaki S, Osaki T, et al. Evidence-based prevention (EBP): Approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism. Anticancer Res. 2003; 23: 1731–1738.
Sobue T, Yamamoto S, Hara M, Sasazuki S, Sasaki S, Tsugane S, et al. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer. 2002; 99: 245–251.
Oyama T, Mitsudomi T, Kawamoto T, Ogami A, Osaki T, Kodama Y, et al. Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Int Arch Occup Environ Health. 1995; 67: 253–256.
Oyama T, Kawamoto T, Mizoue T, Nishida K, Osaki T, Sugio K, et al. p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J. Oncol. 1997; 11: 305–309.
Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T, et al. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res. 1997; 17: 583–587.
Oyama T, Osaki T, Mitsudomi T, Ogawa R, Nakanishi R, Sugio K, et al. p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med. 1998; 1: 823–826.
Oyama T, Osaki T, Nose N, Ichiki Y, Inoue M, Imoto H, et al. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in nonsmall cell lung carcinoma. Anticancer Res. 2000; 20: 505–510.
Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M, Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996; 56: 72–76.
Oyama T, Kagawa N, Kim Y-D, Matsumoto A, Isse T, Kawamoto T. Lung cancer and CYP1A1 or GSTM1 polymorphism. Environ Health Prev Med. 2003; 7: 230–234.
Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res. 2001; 482: 11–19.
Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 1996; 56: 3725–3730.
Crawford EL, Weaver DA, DeMuth JP, Jackson CM, Khuder SA, Frampton MW, et al. Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. Carcinogenesis. 1998; 19: 1867–1871.
Oyama T, Isse T, Kagawa N, Kinaga T, Kim YD, Morita M, et al. Tissue-distribution of aldehyde dehydrogenase 2 and effects of the ALDH2 gene-disruption on the expression of enzymes involved in alcohol metabolism. Front Biosci. 2005; 10: 951–960.
Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol. 2002; 32: 391–411.
Berge G, Mollerup S, OVrebo S, Hewer A, Phillips DH, Eilertsen E, et al. Role of estrogen receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung. Lung Cancer. 2004; 45: 289–297.
Port JL, Yamaguchi K, Du B, De Lorenzo M, Chang M, Heerdt PM, et al. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis. 2004; 25: 2275–2281.
Runge DM, Stock TW, Lehmann T, Taege C, Bernauer U, Stolz DB, et al. Expression of cytochrome P450 2E1 in normal human bronchial epithelial cells and activation by ethanol in culture. Arch Toxicol. 2001; 75: 335–337.
Raunio H, Hakkola J, Hukkanen J, Lassila A, Paivarinta K, Pelkonen O, et al. Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol. 1999; 51: 412–417.
Raunio H, Hakkola J, Pelkonen O. Regulation of CYP3A genes in the human respiratory tract. Chem Biol Interact. 2005; 151: 53–62.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is based upon the research that was given Encouragement Award at the 75th Annual Meeting of the Japanese Society for Hygiene held in Niigata, Japan on March 27–30, 2005.
Rights and permissions
About this article
Cite this article
Oyama, T., Isse, T., Murakami, T. et al. Evidence-based prevention (EBP): A review of cytochrome P450 expression in the bronchial epithelium and new approach to lung cancer prevention. Environ. Health Prev. Med. 11, 97–101 (2006). https://doi.org/10.1265/ehpm.11.97
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1265/ehpm.11.97